Can Fite Biopharma Ltd Share Price Today: Live Updates & Key Insights

Can Fite Biopharma Ltd share price today is $3.17, up -4.8%. The stock opened at $3.32 against the previous close of $3.33, with an intraday high of $3.32 and low of $3.17.

Can Fite Biopharma Ltd Share Price Chart

Can Fite Biopharma Ltd

us-stock
To Invest in {{usstockname}}
us-stock

Can Fite Biopharma Ltd Share Price Performance

$3.17 -0.048(-4.8%) CANF at 23 Mar 2026 12:22 PM Biotechnology
Lowest Today 3.17
Highest Today 3.32
Today’s Open 3.32
Prev. Close 3.33
52 Week High 36.40
52 Week Low 3.15
Day’s Range: Low 3.17 High 3.32
52-Week Range: Low 3.15 High 36.40
1 day return -
1 Week return -8.83
1 month return -30.28
3 month return +1201.34
6 month return +406.0
1 year return +97.53
3 year return +39.13
5 year return -87.87
10 year return -

Can Fite Biopharma Ltd Institutional Holdings

Can Fite Biopharma Ltd Market Status

Strong Buy: 2

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Can Fite Biopharma Ltd Fundamentals

Market Cap 15.24 M

PB Ratio 1.6754

PE Ratio 0.0

Enterprise Value 0.81 M

Total Assets 9.12 M

Volume 49902

Can Fite Biopharma Ltd Company Financials

Annual Revenue FY23:785000 0.8M, FY22:810000 0.8M, FY21:853000 0.9M, FY20:763000 0.8M, FY19:2032000 2.0M

Annual Profit FY23:null 0.0M, FY22:810000 0.8M, FY21:853000 0.9M, FY20:763000 0.8M, FY19:2032000 2.0M

Annual Net worth FY23:-9001000 -9.0M, FY22:-10236000 -10.2M, FY21:-12595000 -12.6M, FY20:-14806000 -14.8M, FY19:-13052000 -13.1M

Quarterly Revenue Q2/2025:101000 0.1M, Q1/2025:101000 0.1M, Q2/2024:158000 0.2M, Q4/2023:155000 0.2M, Q3/2023:196000 0.2M

Quarterly Profit Q2/2025:101000 0.1M, Q1/2025:101000 0.1M, Q2/2024:158000 0.2M, Q4/2023:155000 0.2M, Q3/2023:196000 0.2M

Quarterly Net worth Q2/2025:-2438000 -2.4M, Q1/2025:-2438000 -2.4M, Q2/2024:-1978500 -2.0M, Q4/2023:-1652000 -1.7M, Q3/2023:-1762000 -1.8M

About Can Fite Biopharma Ltd & investment objective

Company Information Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.

Organisation Biotechnology

Employees 5

Industry Biotechnology

CEO Mr. Motti Farbstein

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Can Fite Biopharma Ltd FAQs

What is the share price of Can Fite Biopharma Ltd today?

The current share price of Can Fite Biopharma Ltd is $3.17.

Can I buy Can Fite Biopharma Ltd shares in India?

Yes, Indian investors can buy Can Fite Biopharma Ltd shares by opening an international trading and demat account with Motilal Oswal.

How to buy Can Fite Biopharma Ltd shares in India?

You can easily invest in Can Fite Biopharma Ltd shares from India by:

Can I buy fractional shares of Can Fite Biopharma Ltd?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Can Fite Biopharma Ltd?

Can Fite Biopharma Ltd has a market cap of $15.24 M.

In which sector does Can Fite Biopharma Ltd belong?

Can Fite Biopharma Ltd operates in the Biotechnology sector.

What documents are required to invest in Can Fite Biopharma Ltd stocks?

To invest, you typically need:

What is the PE and PB ratio of Can Fite Biopharma Ltd?

The PE ratio of Can Fite Biopharma Ltd is N/A and the PB ratio is 1.68.